In a trial of 38, 546 people 60 and up, sponsored by the VA and Merck, a single dose reduced the incidence of shingles over the next three years by half and slashed severe cases of postshingles pain (usually lasting three months or more) by two-thirds, according to the results in the New England Journal of Medicine (June 2, 2005).
FORBES: Magazine Article